Pablo Tebas

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)
    Pablo Tebas
    Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 45:193-200. 2007
  2. ncbi request reprint Interventions for body habitus changes associated with HIV infection and its treatment
    Pablo Tebas
    University of Pennsylvania, AIDS Clinical Research Unit, 3451 Walnut Street, Philadelphia, PA 19104, USA
    Curr HIV/AIDS Rep 4:86-92. 2007
  3. ncbi request reprint Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function
    Pablo Tebas
    University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 47:342-5. 2008
  4. pmc Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk
    Pablo Tebas
    University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 3:e2021. 2008
  5. doi request reprint HIV and cardiometabolic abnormalities: new perspectives and treatment update
    Pablo Tebas
    University of Pennsylvania, AIDS Clinical Trials Unit, Philadelphia, PA 19104 4283, USA
    J Acquir Immune Defic Syndr 49:S77-8. 2008
  6. ncbi request reprint Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options
    Pablo Tebas
    AIDS Clinical Trials Unit, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Acquir Immune Defic Syndr 49:S86-92. 2008
  7. pmc Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110
    P Tebas
    University of Pennsylvania, Philadelphia, USA
    J Antimicrob Chemother 63:998-1005. 2009
  8. ncbi request reprint Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals
    Pablo Tebas
    University of Pennsylvania School of Medicine, Philadelphia, USA
    AIDS 24:2187-92. 2010
  9. pmc A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults
    Pablo Tebas
    Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 6:e24180. 2011
  10. ncbi request reprint Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    J Acquir Immune Defic Syndr 45:508-14. 2007

Research Grants

  1. Mitochondria And Metabolic Complications Of HIV
    Pablo Tebas; Fiscal Year: 2006
  2. AIDS CLINICAL TRIALS UNIT
    Pablo Tebas; Fiscal Year: 2007
  3. CORE--DEVELOPMENTAL FACILITY
    Pablo Tebas; Fiscal Year: 2008
  4. Human Studies of NK-1R anatogonists in HIV-1 (project 4)
    Pablo Tebas; Fiscal Year: 2008

Detail Information

Publications78

  1. ncbi request reprint Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)
    Pablo Tebas
    Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 45:193-200. 2007
    ..Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication...
  2. ncbi request reprint Interventions for body habitus changes associated with HIV infection and its treatment
    Pablo Tebas
    University of Pennsylvania, AIDS Clinical Research Unit, 3451 Walnut Street, Philadelphia, PA 19104, USA
    Curr HIV/AIDS Rep 4:86-92. 2007
    ..This review discusses the current management of these complications of HIV and its treatment. For the purpose of clarity in this review, we have divided the interventions according to the predominant phenotype of the individual...
  3. ncbi request reprint Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function
    Pablo Tebas
    University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 47:342-5. 2008
    ..The aim of this study was to examine the influence of kidney disease and hemodialysis on the pharmacokinetics ofenfuvirtide...
  4. pmc Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk
    Pablo Tebas
    University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 3:e2021. 2008
    ..Our goal was to evaluate fasting metabolic changes associated with interruption of antiretroviral therapy and relate them to changes of immune activation markers and cardiovascular risk...
  5. doi request reprint HIV and cardiometabolic abnormalities: new perspectives and treatment update
    Pablo Tebas
    University of Pennsylvania, AIDS Clinical Trials Unit, Philadelphia, PA 19104 4283, USA
    J Acquir Immune Defic Syndr 49:S77-8. 2008
  6. ncbi request reprint Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options
    Pablo Tebas
    AIDS Clinical Trials Unit, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Acquir Immune Defic Syndr 49:S86-92. 2008
    ..Optimization of antiretroviral treatment regimens for HIV-infected patients with or at increased risk for development of abnormalities in glucose metabolism is discussed...
  7. pmc Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110
    P Tebas
    University of Pennsylvania, Philadelphia, USA
    J Antimicrob Chemother 63:998-1005. 2009
    ..Switching a thymidine analogue to a non-thymidine analogue or changing to a nucleoside-sparing regimen has been shown to partially reverse peripheral lipoatrophy. The current study evaluated both approaches...
  8. ncbi request reprint Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals
    Pablo Tebas
    University of Pennsylvania School of Medicine, Philadelphia, USA
    AIDS 24:2187-92. 2010
    ..To evaluate the safety and immunogenicity of the H1N1 2009 vaccine in HIV-positive individuals...
  9. pmc A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults
    Pablo Tebas
    Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 6:e24180. 2011
    ..Neurokinin-1 receptor (NK1R) antagonists have anti-HIV activity in monocyte-derived macrophages, decrease CCR5 expression and improve natural killer cell function ex vivo. Aprepitant is a NK1R antagonist approved by FDA as an antiemetic...
  10. ncbi request reprint Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    J Acquir Immune Defic Syndr 45:508-14. 2007
    ..Long-term regional body fat outcomes have not been well described in randomized antiretroviral drug trials...
  11. ncbi request reprint Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    Clin Infect Dis 45:120-6. 2007
    ..The effects of initiation of different antiretroviral regimens on testosterone levels and changes in fat-free mass have not been reported...
  12. ncbi request reprint Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus
    Maria Ristig
    Division of Infectious Diseases, Hepatology Program, Washington University School of Medicine, St Louis, Missouri, USA
    AIDS Patient Care STDS 17:439-42. 2003
    ..The patient was subsequently removed from the liver transplant program and has not suffered from any further hepatic complications...
  13. ncbi request reprint Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients
    Vincent Lo Re
    Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 44:315-20. 2007
    ..The prevalence of occult HBV in HIV-infected patients remains controversial, and the risk factors and clinical significance are unknown...
  14. doi request reprint Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial
    Noah McKittrick
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Intern Med 158:19-26. 2013
    ..HIV-infected persons have less robust antibody responses to influenza vaccines...
  15. pmc Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
    ..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients...
  16. ncbi request reprint Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy
    Marisa T Gerber
    Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA
    Clin Infect Dis 39:419-25. 2004
    ..Extended release (ER)-niacin therapy, which has been associated with reduced glucose tolerance in human immunodeficiency virus (HIV)-seronegative individuals, has not been evaluated in the HIV-infected population...
  17. doi request reprint Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy
    Todd Hulgan
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    J Infect Dis 197:858-66. 2008
    ..Mitochondrial haplogroups and hemochromatosis gene (HFE) polymorphisms have been associated with ART-induced neuropathy. We assessed relationships between these variants and lipoatrophy...
  18. pmc Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density
    Kristine M Erlandson
    aUniversity of Colorado Anschutz Medical Campus Aurora, Colorado bHarvard School of Public Health, Boston cBrigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts dLos Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California eUniversity of Pennsylvania, Philadelphia, Pennsylvania fGilead Sciences, Foster City, California gViiV Healthcare, Research Triangle, North Carolina hSocial and Scientific Systems, Inc, Silver Spring, Maryland iCase Western Reserve University, Cleveland, Ohio, USA
    AIDS 27:2069-79. 2013
    ..To compare the effect that initiating different antiretroviral therapy (ART) regimens has on weight, BMI, and lean body mass (LBM) and explore how changes in body composition are associated with bone mineral density (BMD)...
  19. pmc Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial
    Valerianna K Amorosa
    Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
    HIV Clin Trials 14:274-83. 2013
    ....
  20. pmc Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection
    Vincent Lo Re
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Hepatology 56:1688-98. 2012
    ..56; 95% CI: 2.93-4.32; males, 18-39 years: HR, 2.40; 95% CI: 2.02-2.84)...
  21. pmc Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV
    Pablo Tebas
    Department of Medicine and Center for AIDS Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
    Blood 121:1524-33. 2013
    ..We conclude that gene-modified T cells have the potential to decrease the fitness of HIV-1 and conditionally replicative lentiviral vectors have a promising safety profile in T cells...
  22. ncbi request reprint Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection
    Kristin Mondy
    Washington University School of Medicine, Division of Infectious Diseases, St Louis, MO, USA
    J Acquir Immune Defic Syndr 38:426-31. 2005
    ..We conducted a 48-week prospective, randomized, open-label study to evaluate the effects of alendronate, vitamin D, and calcium supplementation on bone mineral density (BMD) in patients with HIV infection...
  23. pmc Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells
    Gary P Wang
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6076, USA
    Mol Ther 17:844-50. 2009
    ....
  24. pmc Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection
    Zsofia Szep
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, USA
    AIDS 25:525-9. 2011
    ..Low vitamin D levels increase the risk of type 2 diabetes mellitus, and vitamin D supplementation has been shown to decrease the risk of type 2 diabetes mellitus in patients without HIV infection...
  25. ncbi request reprint Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, Indiana, USA
    AIDS 19:1807-18. 2005
    ..To determine if particular components of antiretroviral drug regimens are associated with greater insulin resistance, dyslipidemia, and peripheral lipoatrophy...
  26. ncbi request reprint A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia
    Valerianna Amorosa
    Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104 6073, USA
    J Acquir Immune Defic Syndr 39:557-61. 2005
    ..Obesity and HIV infection are ongoing epidemics in the United States. Obesity predisposes to diabetes and cardiovascular disease, which are complications also associated with HIV and/or its treatment...
  27. doi request reprint Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis
    Gregory P Bisson
    Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, and The Children s Hospital of Philadelphia, Philadelphia, PA 19104 6021, USA
    Clin Infect Dis 56:1165-73. 2013
    ..This study tested the hypothesis that initiation of ART during initial treatment of HIV/CM would improve CSF clearance of C. neoformans...
  28. ncbi request reprint Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro
    Xu Wang
    Division of Allergy and Immunology, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Neuroimmune Pharmacol 2:42-8. 2007
    ..Aprepitant is in clinical use for the prevention of nausea and vomiting associated with cancer chemotherapy or following surgical procedures...
  29. ncbi request reprint Bone disease and HIV infection
    Valerianna Amorosa
    Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Clin Infect Dis 42:108-14. 2006
    ....
  30. pmc Massively parallel pyrosequencing in HIV research
    Frederic D Bushman
    Department of Microbiology, University of Pennsylvania School of Medicine, 3610 Hamilton Walk, Philadelphia, PA 19104 6076, USA
    AIDS 22:1411-5. 2008
  31. ncbi request reprint Emerging bone problems in patients infected with human immunodeficiency virus
    Kristin Mondy
    Division of Infectious Diseases, AIDS Clinical Trials Unit, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Clin Infect Dis 36:S101-5. 2003
    ..Hormone replacement and antiresorptive therapies might be also indicated...
  32. pmc Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men
    Vincent Lo Re
    Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    AIDS 23:2191-8. 2009
    ..Few studies have examined the impact of viral hepatitis on bone mineral density (BMD), and none have done so among HIV-infected patients. Our objective was to determine whether viral hepatitis was associated with low BMD in HIV...
  33. doi request reprint Impact of transitioning from HIV clinical trials to routine medical care on clinical outcomes and patient perceptions
    Baligh R Yehia
    Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
    AIDS Care 24:769-77. 2012
    ..Patients without a healthy fear of transitioning from ART-RCTs to routine care may be at increased risk of viral failure. Focus should be given to assisting patients during this transition...
  34. ncbi request reprint Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women
    Salome N Juethner
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63108, USA
    J Acquir Immune Defic Syndr 32:153-6. 2003
    ....
  35. pmc DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations
    Christian Hoffmann
    Department of Microbiology, University of Pennsylvania School of Medicine, 3610 Hamilton Walk, Philadelphia, PA 19104 6076, USA
    Nucleic Acids Res 35:e91. 2007
    ....
  36. pmc Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration
    Livio Azzoni
    1HIV 1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA
    J Infect Dis 207:213-22. 2013
    ..Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication...
  37. ncbi request reprint Management of potential neurocysticercosis in patients with HIV infection
    Sashank Prasad
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Clin Infect Dis 42:e30-4. 2006
    ..We report 3 cases and suggest including the CD4+ T lymphocyte count as an important factor in the proper diagnosis and treatment of patients with human immunodeficiency virus and potential neurocysticercosis...
  38. ncbi request reprint Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease
    Robert C Kalayjian
    Division of Infectious Diseases, MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio 44109 1998, USA
    J Infect Dis 192:1577-87. 2005
    ..We have attempted to identify factors associated with T cell reconstitution in response to highly active antiretroviral therapy...
  39. pmc Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism
    Karuppiah Muthumani
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Virol 82:11536-44. 2008
    ..These data demonstrate an important signaling event of Nef in HIV-1 pathogenesis...
  40. pmc The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana
    Gregory P Bisson
    Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 49:227-9. 2008
    ..The objective of this study was to evaluate outcomes among adults with a first episode of cryptococcal meningitis (CM), comparing those on highly active antiretroviral therapy (HAART) with those not on HAART...
  41. ncbi request reprint Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals
    Kristin Mondy
    Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63108, USA
    Clin Infect Dis 36:482-90. 2003
    ..Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors...
  42. ncbi request reprint Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips"
    Rob Roy MacGregor
    Department of Medicine, University of Pennsylvania School of Medicine, 502 Johnson Pavilion, 36th and Hamilton Walk, Philadelphia, PA 19104 6073, USA
    Vaccine 23:2066-73. 2005
    ..04). The decrease in the frequency of transient viremia and failure suggests that DNA immunization with CD8-generating vaccines in HAART-controlled HIV-positive subjects may have therapeutic potential...
  43. ncbi request reprint Is it time to rethink the expanded-access programs for HIV infection?
    Valerianna Amorosa
    University of Pennsylvania, Philadelphia, PA 19104, USA
    J Infect Dis 196:974-7. 2007
    ....
  44. ncbi request reprint Modeling and Simulation Approach to Support Dosing and Study Design Requirements for Treating HIV-Related Neuropsychiatric Disease with the NK1-R Antagonist Aprepitant
    Jeffrey S Barrett
    Divisions of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia Research Institute, Philadelphia, PA 19104, USA
    Curr HIV Res 12:121-31. 2014
    ..The benefit of aprepitant on innate immunity(natural killer cells) and absence of negative effects onex vivo neutrophil chemotaxis alleviates concerns regarding drug dependent inhibition (DDI)-mediated infection risk. ..
  45. pmc A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA AIDS Clinical Trials Group, Statistical and Data Analysis Center, Harvard University School of Public Health, Boston, MA Vaccine and Gene Therapy Institute, Port Saint Lucie, FL Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI Department of Immunology Microbiology, Rush University School of Medicine, Chicago, IL Division of Hematology and Chronic Viral Illness Service, McGill University Health Centre, Montreal, CA Division of Infectious Diseases, Department of Medicine, University of California, San Diego, School of Medicine, San Diego, CA Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN Social and Scienti x fb01 c Systems, Inc, Silver Springs, MD Frontier Sciences, Buffalo, NY and Division of AIDS, NIAID, Bethesda, MD
    J Acquir Immune Defic Syndr 66:399-406. 2014
    ..Palifermin (keratinocyte growth factor), by providing support to the thymic epithelium, promotes lymphopoiesis in animal models of bone marrow transplantation and graft-versus-host disease...
  46. ncbi request reprint Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed
    Maria B Ristig
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63108, USA
    J Infect Dis 186:1844-7. 2002
    ..There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals...
  47. ncbi request reprint Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study
    David A Wohl
    Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA
    Antivir Ther 19:141-7. 2014
    ..Putative mechanisms for an effect of ABC on CVD risk including endothelial dysfunction have been proposed; however, a biological mechanism has not been established...
  48. ncbi request reprint Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
    Roger Bedimo
    Department of Medicine, VA North Texas Healthcare System, Dallas, Texas, USA
    AIDS 26:825-31. 2012
    ..Whereas tenofovir (TDF) exposure has been associated with decreased bone density, it remains unclear whether it is associated with increased risk of osteoporotic fractures...
  49. pmc HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells
    Karuppiah Muthumani
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 187:2932-43. 2011
    ..These data identify a novel mechanism by which HIV exploits the immunosuppressive PD-1 pathway and suggest a new role for virus-infected cells in the local corruption of immune responses required for viral suppression...
  50. ncbi request reprint Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection
    Jeffrey M Jacobson
    Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
    J Infect Dis 188:1804-14. 2003
    ..Studies have reported that plasma human immunodeficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)...
  51. ncbi request reprint Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138
    Michael M Lederman
    Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    J Infect Dis 194:1677-85. 2006
    ..Although the determinants of immune deficiency and immune restoration in chronic human immunodeficiency virus (HIV)-1 infection are not well understood, immune activation has been proposed as being central to the pathogenesis of HIV...
  52. ncbi request reprint Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy
    Eveline C Timmermans
    Primagen, Amsterdam, The Netherlands
    Clin Chem 52:979-87. 2006
    ....
  53. ncbi request reprint Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS Care
    Calvin Cohen
    CRI New England, 23 Miner Street, Boston, Massachusetts 02215 3318, USA
    J Int Assoc Physicians AIDS Care (Chic) 1:141-5. 2002
    ..The opinions expressed in this Consensus Statement represent only those of the Advisory Committee...
  54. pmc Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy
    Andrea S Foulkes
    School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts, United States of America
    PLoS Med 3:e52. 2006
    ..However, the association of race/ethnicity, or candidate gene effects across race/ethnicity, with plasma lipid levels in HIV-1-infected individuals, has not been reported...
  55. ncbi request reprint Fat redistribution and bone abnormalities in HIV-infected patients
    Pablo Tebas
    Washington University, 4511 Forest Park, Suite 304, Saint Louis, MO 63108, USA
    J Int Assoc Physicians AIDS Care (Chic) 2:59-65. 2003
  56. ncbi request reprint Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies
    Pablo Tebas
    Washington University School of Medicine, St Louis, Missouri 63108, USA
    J Infect Dis 186:851-4. 2002
    ..In a multiple regression analysis model, the increase of CD4(+) T cells while receiving therapy and age were independently associated with the rate of CD4(+) T cell loss...
  57. ncbi request reprint On antiretroviral guidelines and evidence based medicine
    Pablo Tebas
    Enferm Infecc Microbiol Clin 20:241-3. 2002
  58. ncbi request reprint Cardiovascular risks of antiretroviral therapies
    Kristin Mondy
    Washington University School of Medicine, Saint Louis, Missouri 63110, USA
    Annu Rev Med 58:141-55. 2007
    ..Optimal selection of metabolically neutral antiretroviral therapies, together with aggressive management of other modifiable coronary risk factors, may improve cardiovascular disease risk in the long term...
  59. ncbi request reprint Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen
    Margaret A Fischl
    AIDS Clinical Research Unit R 60A, Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
    AIDS 21:325-33. 2007
    ..Complex antiretroviral regimens can be associated with increased toxicity and poor adherence. Our aim was to compare the efficacy and safety of switching to two simplified, class-sparing antiretroviral regimens...
  60. ncbi request reprint Genetic analysis implicates resistin in HIV lipodystrophy
    Koustubh Ranade
    Bristol Myers Squibb R and D, Princeton, New Jersey 08543 5400, USA
    AIDS 22:1561-8. 2008
    ..To investigate the role of genetic variation in influencing the risk of metabolic complications associated with highly active antiretroviral therapy (HAART)...
  61. ncbi request reprint A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102
    Keith Henry
    HIV Program, Hennepin County Medical Center and the University of Minnesota, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 42:140-8. 2006
    ..By boosting CD4 T-cell counts, interleukin 2 (IL-2) could safely prolong the duration of treatment interruption (TI) in a CD4-driven strategy...
  62. ncbi request reprint Early intensification with abacavir in subjects at high risk for incomplete viral suppression
    John A Bartlett
    Antivir Ther 8:361-3. 2003
  63. ncbi request reprint Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults
    Judith S Currier
    Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
    AIDS 21:1137-45. 2007
    ..To compare the rate of change in intima-media thickness (IMT) of the carotid artery among uninfected subjects and HIV-infected subjects receiving or not receiving protease inhibitor (PI) regimens over a 144 week period...
  64. ncbi request reprint The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328
    Ronald Mitsuyasu
    Department of Internal Medicine, University of California Los Angeles, USA
    Arch Intern Med 167:597-605. 2007
    ..Interleukin 2 (IL-2) administration increases CD4 counts in persons with higher counts. This study investigated persons with moderately advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy (HAART)...
  65. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  66. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  67. ncbi request reprint Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection
    Pablo Tebas
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    AIDS Res Hum Retroviruses 20:589-94. 2004
    ..Our study supports a pathogenic role for PIs in the development of hypertriglyceridemia and insulin resistance, but a more limited role in the fat redistribution syndrome...
  68. ncbi request reprint A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)
    Richard B Pollard
    University of California Davis Medical Center, Patient Support Services Building, 4150 V Street, Suite G500, Sacramento, CA 95817, USA
    AIDS Res Hum Retroviruses 18:699-704. 2002
    ..Based on this study and other data, combining d4T and ZDV is not recommended...
  69. ncbi request reprint Cure of acute hepatitis C in HIV co-infection?
    Maria B Ristig
    J Clin Gastroenterol 38:303. 2004
  70. ncbi request reprint Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV
    Grace A McComsey
    Rainbow Babies and Children s Hospital and Case Western Reserve University, Cleveland, Ohio, USA
    AIDS 21:2473-82. 2007
    ..Bisphosphonates are currently the mainstay of treatment for postmenopausal and male osteoporosis in HIV-uninfected individuals; however, their efficacy and safety in HIV-infected patients remains unclear...
  71. ncbi request reprint Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care
    Carl J Fichtenbaum
    IAPAC Mon 11:38-46. 2005
    ..Scientific and clinical research, and other data in published literature and abstracts from scientific conferences were considered by strength of evidence. This document represents the consensus agreement of the Advisory Committee...
  72. pmc The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling
    Michael W H Wang
    Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    J Clin Invest 114:206-13. 2004
    ..Thus, ritonavir may represent a bone-sparing PI capable of preventing development of osteopenia in patients currently on HAART...
  73. ncbi request reprint HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D
    Mario Cozzolino
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    AIDS 17:513-20. 2003
    ..The 25- and 1alpha-hydroxylases regulate 1,25(OH) D synthesis and 24-hydroxylase 1,25(OH) D catabolism...
  74. ncbi request reprint Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia
    Kevin E Yarasheski
    Division of Endocrinology, Metabolism and Lipid Research, Washington University Medical School, 660 South Euclid Avenue, Box 8127, St Louis, MO 63110, USA
    Am J Physiol Endocrinol Metab 285:E899-905. 2003
    ..g., central adiposity and hyperinsulinemia) and mediated only partially by factors that influence triglyceride clearance (e.g., lipase activity)...
  75. ncbi request reprint Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial
    Kathleen Mulligan
    Department of Medicine, Division of Endocrinology, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 41:590-7. 2006
    ..We examined intraindividual changes in dual-energy x-ray absorptiometry (DEXA) and anthropometry data over 64 weeks after initiation of antiretroviral therapy (ART)...
  76. ncbi request reprint Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle
    W Keith Henry
    JAMA 296:1523-5. 2006
  77. ncbi request reprint [Delayed diagnosis of HIV infection in the Spanish VACH cohort [1997-2002]]
    Ramón Teira Cobo
    Servicio de Enfermedades Infecciosas, Hospital de Basurto, Bilbao, Espana
    Gac Sanit 21:66-9. 2007
    ..To study the prevalence of delayed diagnosis of HIV infection and associated factors...
  78. ncbi request reprint Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine
    Erik J Uhlmann
    Department of Pathology, Box 8118, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Virol 31:198-203. 2004
    ..Cross resistance is common among the non-nucleoside reverse transcriptase inhibitors (NNRTIs). G190A appears in 5-15% of the patients treated with nevirapine or efavirenz who develop clinical resistance...

Research Grants4

  1. Mitochondria And Metabolic Complications Of HIV
    Pablo Tebas; Fiscal Year: 2006
    ..In order to do this we will use a NASBA based assay to measure the mitochondrial DNA and RNA content in PBMCs, and use 2000 specimens collected longitudinally in 3 large ACTG studies. ..
  2. AIDS CLINICAL TRIALS UNIT
    Pablo Tebas; Fiscal Year: 2007
    ..The investigators have credentials in basic and patient-oriented clinical research. ..
  3. CORE--DEVELOPMENTAL FACILITY
    Pablo Tebas; Fiscal Year: 2008
    ..We are proposing to fund 5 projects each year in years 6-10 of this CFAR, adding a new grant category devoted exclusively to interdisciplinary and/or translational research projects. ..
  4. Human Studies of NK-1R anatogonists in HIV-1 (project 4)
    Pablo Tebas; Fiscal Year: 2008
    ..Assessment depression, anxiety, and sleep quality relative to baseline before and after the administration of aprepitant. ..